<DOC>
	<DOCNO>NCT00692705</DOCNO>
	<brief_summary>The study carry order investigate [ 11C ] AZD2995 , compare [ 11C ] AZD2184 , suitable PET ligand vivo image β amyloid deposition human brain . In study two PET ligand examine healthy volunteer patient Alzheimer 's Disease .</brief_summary>
	<brief_title>Positron Emission Tomography ( PET ) Study With 11CAZD2995 11CAZD2184 , Candidate PET Ligands β Amyloid</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Alzheimer´s Disease patient 5085 year mild moderate AD , clinical progression AD 12 month . Healthy male volunteer : Age 2050 year , Body Mass Index : 1830 kg/m2 . Clinically normal physical finding include normal blood pressure pulse rate . Alzheimer´s Disease patient : significant cerebrovascular disease depression , central nervous system infarct infection lesion clinically significant illness within 2 week study start . administration investigational product effect brain beta amyloid level within 3 month prior study and/or participation PET investigation study D0180C00011 part scientific study past 12 month , . Healthy volunteer ; clinically significant illness within 2 week study start , history psychiatric somatic disease/condition may interfere . first degree relative dementia . Obvious deterioration memory function .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Alzheimer´s Disease</keyword>
	<keyword>amyloid deposit</keyword>
	<keyword>Positron Emission Tomography</keyword>
	<keyword>phase I</keyword>
</DOC>